PE20121643A1 - Polipeptidos del factor ix modificados y usos de los mismos - Google Patents

Polipeptidos del factor ix modificados y usos de los mismos

Info

Publication number
PE20121643A1
PE20121643A1 PE2012000114A PE2012000114A PE20121643A1 PE 20121643 A1 PE20121643 A1 PE 20121643A1 PE 2012000114 A PE2012000114 A PE 2012000114A PE 2012000114 A PE2012000114 A PE 2012000114A PE 20121643 A1 PE20121643 A1 PE 20121643A1
Authority
PE
Peru
Prior art keywords
polypeptide
remains
factor
polypeptides
conjugate
Prior art date
Application number
PE2012000114A
Other languages
English (en)
Spanish (es)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20121643A1 publication Critical patent/PE20121643A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2012000114A 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos PE20121643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31

Publications (1)

Publication Number Publication Date
PE20121643A1 true PE20121643A1 (es) 2012-11-25

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000114A PE20121643A1 (es) 2009-07-31 2010-08-02 Polipeptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2461821A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2013500726A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20120060209A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102573890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010278721A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012002072A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2769258A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2012000238A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20120052A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (3) CU20120018A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2012000030A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201290069A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP12011637A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT201200023A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012001346A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20121643A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG178119A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011014890A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201200716B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323430A1 (en) 2006-12-15 2018-05-23 Baxalta GmbH Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life
HRP20230259T1 (hr) 2008-09-15 2023-04-28 Uniqure Biopharma B.V. Mutant polipeptida faktora ix, njegove primjene i postupak za njegovu proizvodnju
NZ623810A (en) 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
AR082941A1 (es) * 2010-07-30 2013-01-23 Baxter Int Metodo para conjugar un polimero hidrosoluble a una porcion de carbohidrato oxidado de una proteina terapeutica
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
HRP20180124T1 (hr) * 2011-12-19 2018-02-23 Dilafor Ab Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
AU2013348029A1 (en) * 2012-11-20 2015-07-02 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX proteins
KR20150126035A (ko) 2013-03-13 2015-11-10 일라이 릴리 앤드 캄파니 변형된 개 렙틴 폴리펩티드
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
TW202027799A (zh) 2018-10-18 2020-08-01 美商英特利亞醫療公司 用於表現因子ix的組成物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086091A2 (en) * 2001-04-25 2002-10-31 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
EP1694315A4 (en) * 2003-12-03 2009-10-28 Novo Nordisk As FACTOR IX GLYCOPEGYL
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
IN2012DN00908A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-04-03
KR20120060209A (ko) 2012-06-11
US20120164130A1 (en) 2012-06-28
GT201200023A (es) 2014-01-27
CR20120052A (es) 2012-06-04
EA201290069A1 (ru) 2012-07-30
ZA201200716B (en) 2013-07-31
JP2013500726A (ja) 2013-01-10
CU20130057A7 (es) 2013-06-28
DOP2012000030A (es) 2012-02-29
CN102573890A (zh) 2012-07-11
EP2461821A4 (en) 2013-07-03
WO2011014890A1 (en) 2011-02-03
MX2012001346A (es) 2012-02-17
BR112012002072A2 (pt) 2016-11-08
SG178119A1 (en) 2012-03-29
ECSP12011637A (es) 2012-02-29
CL2012000238A1 (es) 2012-10-05
CU20120018A7 (es) 2012-06-21
CU20130058A7 (es) 2013-06-28
AU2010278721A1 (en) 2012-02-16
CA2769258A1 (en) 2011-02-03
EP2461821A1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
PE20091931A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
PE20110426A1 (es) Polipeptidos g-csf bovinos modificados
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
WO2010043650A3 (en) Amino acid sequences targeting human cd4, cxcr4, ccr5, tlr4, alphav integrin, beta3- integrin, betal -integrin, human alpha2- integrin, cd81, sr-bi, claudin-i, claudin-6 and claudin-9, respectively, and neutralizing viral entry
CL2015000060A1 (es) Proteína quimérica que comrpende una proteína del factor von willebrand (vwf), una secuencia xten y una proteina del factor viii; polinucleótido que la codifica; vector; célula huésped; y composición farmacéutica útil en el tratamiento de la hemofilia.
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
ECSP10010551A (es) Polipeptidos modificados del factor ix y usos de los mismos
AR084053A1 (es) Agente terapeutico que induce citotoxicidad
UY33578A (es) PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
BR112012015461A2 (pt) polipeptídeos de somatotropina boviina modificados e seus usos
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
GT200900229A (es) Coagonistas de receptor de glucagón/glp-1
PE20120021A1 (es) Mutantes fgf21
AR092076A1 (es) Proteinas homodimericas
TR201903066T4 (tr) E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
EP4403197A3 (en) Injectable formulations for organ augmentation

Legal Events

Date Code Title Description
FC Refusal